Biomea Fusion Inc. (BMEA), a clinical-stage biopharmaceutical company, is set to announce two data updates for its lead drug candidate Icovamenib this quarter.
Icovamenib is an oral, potent, and selective covalent inhibitor of menin, a key transcriptional regulator known to play a direct role in regulating the growth of beta cells in the pancreas as well as in oncogenic signaling in multiple cancers.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.